Fox Run Management L.L.C. Invests $114,000 in CorMedix Inc. (NASDAQ:CRMD)

Fox Run Management L.L.C. acquired a new stake in CorMedix Inc. (NASDAQ:CRMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 14,114 shares of the company’s stock, valued at approximately $114,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRMD. FMR LLC increased its stake in shares of CorMedix by 54.3% in the third quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after purchasing an additional 1,625 shares during the period. Janney Montgomery Scott LLC acquired a new stake in CorMedix in the 4th quarter valued at approximately $81,000. Aigen Investment Management LP bought a new stake in CorMedix during the 4th quarter valued at $94,000. BNP Paribas Financial Markets boosted its position in CorMedix by 130.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company’s stock worth $97,000 after acquiring an additional 6,761 shares during the period. Finally, Legato Capital Management LLC bought a new position in shares of CorMedix in the fourth quarter worth $97,000. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Stock Up 0.4 %

CRMD opened at $6.74 on Friday. The business has a fifty day simple moving average of $10.43 and a 200-day simple moving average of $9.89. The firm has a market cap of $408.96 million, a PE ratio of -8.32 and a beta of 1.53. CorMedix Inc. has a fifty-two week low of $3.61 and a fifty-two week high of $13.85.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings results on Tuesday, March 25th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. The company had revenue of $30.00 million during the quarter, compared to analysts’ expectations of $27.46 million. CorMedix’s quarterly revenue was up 29900.0% on a year-over-year basis. On average, equities research analysts anticipate that CorMedix Inc. will post -0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday. Leerink Partners started coverage on shares of CorMedix in a report on Friday, March 7th. They issued an “outperform” rating and a $18.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and set a $12.00 target price on shares of CorMedix in a report on Wednesday. Leerink Partnrs raised CorMedix to a “strong-buy” rating in a research note on Friday, March 7th. Finally, D. Boral Capital reissued a “buy” rating and issued a $15.00 price objective on shares of CorMedix in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.14.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.